Case record of a patient with severe atopic dermatitis who showed a good response to dupilumab. every other week. Up to now, she has taken four applications, presenting a great improvement of the disease and her quality of life. There were no adverse effects, nor in the injection site nor of other kind. Patient and her family are very satisfied, and the medical team evaluates that the treatment is being well succeed. The case report described here subsidizes the use of dupilumab in the treatment of severe atopic dermatitis refractory to use of immunosuppressive agents. placebo. The two regimens tested, 300mg subcutaneously every week or 300mg subcutaneously every other week for 16 weeks, were equally effective and safe. The most frequent side effects were injection site reactions and conjunctivitis.( 12 ) It is considered a breakthrough therapy for moderate to severe AD in poorly controlled adults. There are new studies in progress in children. CONCLUSION We report the first case in Brazil using dupilumab, a 6H05 (TFA) new class of drugs for controlling atopic dermatitis, in a patient with severe disease, poorly controlled by commonly used systemic therapies, who, to date, is evolving quite well, with no adverse effects. This full case report supports the usage of dupilumab in dealing with serious atopic dermatitis, refractory to the usage of systemic immunosuppressants. Sources 1. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of years as a child atopic dermatitis in an over-all inhabitants. J Am Acad Dermatol. 1994;30(1):35C39. [PubMed] [Google Scholar] 2. Silverberg JI, Hanifin JM. Adult dermatitis prevalence and organizations with asthma and various other health insurance and demographic elements: a US population-based 6H05 (TFA) research. J Allergy Clin Immunol. 2013;132(5):1132C1138. [PubMed] [Google Scholar] 3. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483C1494. [PubMed] [Google Scholar] 4. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, Svensson A, Barbarot S, von Kobyletzki L, Taieb A, de Bruin-Weller M, Werfel T, Trzeciak M, Vestergard 6H05 (TFA) C, Band J, Darsow U. Western european Task Power on Atopic Dermatitis/EADV Dermatitis Task Power. ETFAD/EADV Eczema job force 2015 placement paper on medical diagnosis and treatment of atopic dermatitis in adult and paediatric sufferers. J Eur Acad Dermatol Venereol. 2016;30(5):729C747. [PubMed] [Google Scholar] 5. Band J, Alomar A, Bieber 6H05 (TFA) T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Sch?fer T, Schwennesen T, Seidenari S, Simon D, St?nder S, Stingl G, Szalai S, Szepietowski JC, Ta?eb A, Werfel T, Wollenberg A, Darsow U. Western european Dermatology Forum; Western european Academy of Venereology and Dermatology; European Task Power on Atopic Dermatitis; Western european Federation of Allergy; Western european Culture of Pediatric Dermatology; Asthma and GlobalAllergy Western european Network. Suggestions for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176C1193. [PubMed] [Google Scholar] 6. Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb) 2017;7(1):1C23. [PMC free article] [PubMed] [Google Scholar] 7. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF. AmericanAcademy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and Rabbit polyclonal to NF-kappaB p105-p50.NFkB-p105 a transcription factor of the nuclear factor-kappaB ( NFkB) group.Undergoes cotranslational processing by the 26S proteasome to produce a 50 kD protein. treatment with phototherapy and systemic brokers. J Am Acad Dermatol. 2014;71(2):327C349. [PMC free article] [PubMed] [Google Scholar] 8. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New.